NASDAQ
22.29USD
-0.44 (-1.94%)
We have scored 13 news catalysts on Viridian Therapeutics, Inc. (VRDN) over the past 12 months. The biggest single-day move next to one of them came Apr 6, 2026, when VRDN closed −26.2%: “Why Is Viridian Therapeutics Stock Sinking Monday?”. Coverage across the window leans positive (average ticker sentiment +0.21). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.5B
P/E
—
EPS
—
Beta
0.96
52W range
13.18-34.29
Day range
21.99–22.61
Open
22.40
Prev close
22.73
Volume
1.3M
Avg volume
2.2M
Dividend
0.00
IPO
2014-06-18
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Viridian Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for VRDN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
